Epi One develops a DNA-based biomarker identification platform that utilizes a simple blood draw and PCR testing to provide accurate cancer diagnoses within six hours. This technology addresses the delays and inaccuracies of traditional cancer screening methods, significantly improving early detection and treatment outcomes for patients.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer screening methods often involve lengthy turnaround times, high costs, and potential inaccuracies, leading to delayed diagnoses and poorer patient outcomes. Current techniques like X-rays, CAT scans, and genomic sequencing can take days or even months to produce results, hindering timely treatment.
Solution
Epi One offers a DNA-based biomarker identification platform designed for rapid and accurate cancer diagnoses. Utilizing a simple blood draw and PCR testing, the technology aims to deliver highly accurate test results in as little as six hours. This approach enables earlier detection, more appropriate treatment strategies, and potentially higher survival rates. The platform focuses on identifying key biomarkers to provide a clearer picture of a patient's condition, facilitating timely intervention.
Target Audience
The primary target audience includes healthcare providers, oncologists, and diagnostic laboratories seeking faster, more accurate, and affordable cancer screening solutions.
Features
- DNA-based biomarker identification technology
- Simple blood draw procedure
- PCR testing methodology
- Results available in approximately six hours
- Detection using fewer than 10 biomarkers per test